Vaccine for typhoid and invasive Salmonella shows promise in phase 1 trial
A novel trivalent vaccine targeting typhoid fever and invasive non-typhoidal Salmonella (iNTS) infections has demonstrated promising safety and robust immune responses in a Phase 1 human trial. Developed by the University of Maryland and Bharat Biotech, the vaccine offers potential for enhanced protection against deadly childhood infections prevalent in regions like Africa.